This annual award recognizes outstanding and sustained contributions to the field of CMC regulatory science. A nominee must have made significant contributions/impact to the advancement of scientific principles, applied technologies and/or science-based regulations in the areas of manufacturing process/technology development, characterization, analysis and/or quality of biotechnology-derived pharmaceuticals. The awardees’ achievements must have been instrumental in enabling the availability of high quality life-saving medicines derived from recombinant technology on a global basis. The award consists of a plaque, and reimbursement of reasonable travel expenses and complimentary registration to the WCBP annual meeting in which the award is presented.
A sub-committee of CASSS' board of directors chaired by Wassim Nashabeh with membership of John Frenz, John Dougherty, Nadine Ritter and Mark Schenerman and support from the CASSS executive director Stephanie Flores will nominate individuals that meet the award citation requirements, and subsequently make a (unanimous) selection for endorsement by the CASSS Board by September of each year. Members of the CASSS Board of Directors are not eligible for nomination.